Study Title and Description
Raloxifene is not associated with biologically relevant changes in hot flushes in postmenopausal women for whom therapy is appropriate.
Key Questions Addressed
|3||Key Question 3. What are the harms of using medications to reduce risk for primary breast cancer? Key Question 3a. Do harms of risk-reducing medications vary by timing of initiation and/or duration of use? Key Question 3b. Do harms of risk-reducing medications persist beyond discontinuation of use?|
Primary Publication Information
|Title||Raloxifene is not associated with biologically relevant changes in hot flushes in postmenopausal women for whom therapy is appropriate.|
|Author||Palacios S., Farias ML., Luebbert H., Gomez G., Yabur JA., Quail DC., Turbi C., Kayath MJ., Almeida MJ., Mönnig E., Nickelsen T.|
|Country||Instituto Palacios, Madrid, Spain.|
Pubmed ID: 15295352
Secondary Publication Information
There are currently no secondary publications defined for this study.
Extraction Form: Key Questions 1-4
Results & Comparisons
No Results found.